A Systematic Review and Network Meta-Analysis of Chinese Trials on Antihypertensive Medications for Managing Hyperuricemia in Hypertensive Patients - Scorecard - MDSpire
Advertisement
A Systematic Review and Network Meta-Analysis of Chinese Trials on Antihypertensive Medications for Managing Hyperuricemia in Hypertensive Patients
Clinical Scorecard: A Systematic Review and Network Meta-Analysis of Chinese Trials on Antihypertensive Medications for Managing Hyperuricemia in Hypertensive Patients
At a Glance
Category
Detail
Condition
Hypertension with Hyperuricemia
Key Mechanisms
Antihypertensive agents' effects on serum uric acid levels.
Target Population
Hypertensive patients with hyperuricemia in China.
Care Setting
Clinical settings in China.
Key Highlights
Prevalence of hyperuricemia in hypertensive patients in China is 38.7%.
Losartan is more effective than other antihypertensive agents in reducing serum uric acid levels.
Diuretics, β-blockers, and α-blockers may increase hyperuricemia risk.
Calcium channel blockers and ACE inhibitors show no significant effect on hyperuricemia.
A significant gap exists in global evidence outside of Chinese populations.
Guideline-Based Recommendations
Diagnosis
Hypertension defined as systolic BP ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg.
Hyperuricemia diagnosed per 2020 Chinese Guidelines.
Management
Consider losartan as a first-line treatment for hypertensive patients with hyperuricemia.
Monitoring & Follow-up
Regular monitoring of serum uric acid levels in hypertensive patients.
Risks
Increased cardiovascular disease and renal insufficiency risk associated with hyperuricemia.
Patient & Prescribing Data
Adults aged ≥ 18 years with both hypertension and hyperuricemia.
Combination therapies may enhance urate-lowering efficacy.
Clinical Best Practices
Utilize evidence-based guidelines for managing hypertension and hyperuricemia.
Incorporate regular follow-ups to assess treatment efficacy and adjust medications accordingly.
